- Home
- JTAI vs KPRX Comparison
JTAI vs KPRX Comparison
Compare JTAI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- KPRX
- Stock Information
- Founded
- JTAI 2018
- KPRX 1998
- Country
- JTAI United States
- KPRX United States
- Employees
- JTAI N/A
- KPRX N/A
- Industry
- JTAI Blank Checks
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- JTAI Finance
- KPRX Health Care
- Exchange
- JTAI Nasdaq
- KPRX Nasdaq
- Market Cap
- JTAI 9.9M
- KPRX 9.1M
- IPO Year
- JTAI N/A
- KPRX N/A
- Fundamental
- Price
- JTAI $4.21
- KPRX $3.08
- Analyst Decision
- JTAI
- KPRX Strong Buy
- Analyst Count
- JTAI 0
- KPRX 1
- Target Price
- JTAI N/A
- KPRX $10.00
- AVG Volume (30 Days)
- JTAI 429.0K
- KPRX 1.3M
- Earning Date
- JTAI 05-15-2025
- KPRX 05-09-2025
- Dividend Yield
- JTAI N/A
- KPRX N/A
- EPS Growth
- JTAI N/A
- KPRX N/A
- EPS
- JTAI N/A
- KPRX N/A
- Revenue
- JTAI $13,648,668.00
- KPRX $20,000.00
- Revenue This Year
- JTAI $13.37
- KPRX N/A
- Revenue Next Year
- JTAI $201.13
- KPRX N/A
- P/E Ratio
- JTAI N/A
- KPRX N/A
- Revenue Growth
- JTAI N/A
- KPRX N/A
- 52 Week Low
- JTAI $2.30
- KPRX $2.51
- 52 Week High
- JTAI $166.50
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- JTAI 52.14
- KPRX 48.79
- Support Level
- JTAI $3.85
- KPRX $2.90
- Resistance Level
- JTAI $4.70
- KPRX $4.18
- Average True Range (ATR)
- JTAI 0.30
- KPRX 0.26
- MACD
- JTAI 0.04
- KPRX 0.00
- Stochastic Oscillator
- JTAI 53.77
- KPRX 19.12
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.